default author photo

Pablo Berlanga

Gustave Roussy

Villejuif

France

SCHOLARLY PAPERS

2

DOWNLOADS

203

TOTAL CITATIONS

0

Scholarly Papers (2)

Actions:
Email selected abstracts
1.

Chemo-Immunotherapy with Dinutuximab Beta in Patients with Progressive High-Risk Neuroblastoma: Does Chemotherapy Backbone Matter?

Number of pages: 18 Posted: 30 Jan 2024
Patricia Raiser, Gudrun Schleiermacher, Marion Gambart, Benoit Dumont, Anne-Sophie Desfachelles, Estelle Thebaud, Julie Tandonnet, C. Pasqualini, Stéphanie Proust, Natacha Entz-Werle, Isabelle Aerts, Lee Aymar Ndounga-Diakou, Arnaud Petit, Chloe Puiseux, Leslie Andry, Jeremie Rouger, Ludovic Mansuy, Joy Benadiba, Frédéric Millot, Claire Pluchart, Salim Laghouati, Birgit Geoerger, Gilles Vassal, Dominique Valteau-Couannet and Pablo Berlanga
Gustave Roussy, PSL Research University - Institut Curie, Toulouse University Hospital, Institut d’Hématologie et d’Oncologie Pédiatrique (iHOPe) - Centre Léon Bérard, University of Lille II - Centre Oscar Lambret, Pediatric Immuno-Hemato-Oncology Unit, CHU Nantes, University of Bordeaux - CHU de Bordeaux, Gustave Roussy, University Hospital of Fort de France, Les Hôpitaux Universitaires de Strasbourg, PSL Research University - Institut Curie, Gustave Roussy, AP-HP Hôpital Trousseau, Université de Rennes 1 - Rennes University Hospital, Amiens Picardie University Hospital, University Hospital, Caen, Children's Hospital of Brabois, Nice University Hospital, Université de Poitiers - Centre Hospitalier Universitaire de Poitiers, Centre Hospitalier Universitaire Reims (CHU Reims), Gustave Roussy, Gustave Roussy, Gustave Roussy, Gustave Roussy and Gustave Roussy
Downloads 108 (649,907)

Abstract:

Loading...

Neuroblastoma, immunotherapy, dinutuximab beta, chemotherapy, relapse, real-world data.

2.

Potential Benefit of New Target Inhibitors in Neurotrophic Tropomyosin Receptor Kinase Fusion Positive Tumors: A Historical Cohort Analysis

Downloads 95 (715,072)

Potential Benefit of New Target Inhibitors in Neurotrophic Tropomyosin Receptor Kinase Fusion Positive Tumors: A Historical Cohort Analysis

Number of pages: 28 Posted: 14 Apr 2022
Lauriane Lemelle, Delphine Guillemot, Anne-Laure Hermann, Arnaud Gauthier, Matthieu Carton, Nadège Corradini, Angélique Rome, Pablo Berlanga, Anne Jourdain, Aude Marie Cardine, Sarah Jannier, Hélène Boutroux, Anne-Sophie Desfachelles, Isabelle Aerts, Birgit Geoerger, Marie Karanian, François Doz, Hervé J. Brisse, Gudrun Schleiermacher, olivier delattre, Gaelle Pierron and Daniel Orbach
PSL Research University - Institut Curie, PSL Research University - Institut Curie, PSL Research University - Institut Curie, PSL Research University - Institut Curie, PSL Research University - Institut Curie, Clocheville Hospital - Pediatric Onco-Hematology Service, Aix-Marseille University - Assistance Publique-Hopitaux de Marseille, Gustave Roussy, Hospital Sant Joan de Deu - Department of Pediatric Hematology and Oncology, Université d'Amiens - Department of Oncology-Hematology and Pediatric Immunology, University of Strasbourg - Department of Hematology and Oncology, Hospital Sant Joan de Deu - Department of Pediatric Hematology and Oncology, University of Lille II - Centre Oscar Lambret, PSL Research University - Institut Curie, Gustave Roussy, University of Claude Bernard Lyon 1 - Centre Léon Bérard, PSL Research University - Institut Curie, PSL Research University - Institut Curie, PSL Research University - Institut Curie, PSL Research University - Institut Curie, PSL Research University - Institut Curie and PSL Research University - SIREDO Oncology Center
Downloads 53 (1,049,673)

Abstract:

Loading...

Neurotrophic Tropomyosin Receptor Kinase, Fusion Transcript Tumor, TRK Inhibitor, Infantile Fibrosarcoma, burden of therapy.

Potential Benefit of New Target Inhibitors in Neurotrophic Tropomyosin Receptor Kinase Fusion Positive Tumors: A Historical Cohort Analysis

Number of pages: 20 Posted: 10 May 2022
Lauriane Lemelle, Delphine Guillemot, Anne-Laure Hermann, Arnaud Gauthier, Matthieu Carton, Nadège Corradini, Angélique Rome, Pablo Berlanga, Anne Jourdain, Aude Marie Cardine, Sarah Jannier, Hélène Boutroux, Anne-Sophie Desfachelles, Isabelle Aerts, Birgit Geoerger, Marie Karanian, François Doz, Hervé J. Brisse, Gudrun Schleiermacher, olivier delattre, Gaelle Pierron and Daniel Orbach
PSL Research University - Institut Curie, PSL Research University - Institut Curie, PSL Research University - Institut Curie, PSL Research University - Institut Curie, PSL Research University - Institut Curie, Clocheville Hospital - Pediatric Onco-Hematology Service, Aix-Marseille University - Assistance Publique-Hopitaux de Marseille, Gustave Roussy, Hospital Sant Joan de Deu - Department of Pediatric Hematology and Oncology, Université d'Amiens - Department of Oncology-Hematology and Pediatric Immunology, University of Strasbourg - Department of Hematology and Oncology, Hospital Sant Joan de Deu - Department of Pediatric Hematology and Oncology, University of Lille II - Centre Oscar Lambret, PSL Research University - Institut Curie, Gustave Roussy, University of Claude Bernard Lyon 1 - Centre Léon Bérard, PSL Research University - Institut Curie, PSL Research University - Institut Curie, PSL Research University - Institut Curie, PSL Research University - Institut Curie, PSL Research University - Institut Curie and PSL Research University - SIREDO Oncology Center
Downloads 42 (1,183,247)

Abstract:

Loading...

Neurotrophic Tropomyosin Receptor Kinase, Fusion Transcript Tumor, TRK Inhibitor, Infantile Fibrosarcoma, burden of therapy.